borderline significantP = 0.049
There was, however, a borderline significant sex difference between the two groups, with 73.0% male patients in the tirofiban group and 51.2% male patients in the control group ( P = 0.049).
There was, however, a borderline significant sex difference between the two groups, with 73.0% male patients in the tirofiban group and 51.2% male patients in the control group ( P = 0.049).